☆ 4.5 Article

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

JOURNAL OF RHEUMATOLOGY (2014)

Get Full Text
Add to Collection

Journal

JOURNAL OF RHEUMATOLOGY
Volume 41, Issue 2, Pages 300-309

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.121368

Keywords

BELIMUMAB; SELENA-SLEDAI SLE RESPONDER INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS

Categories

Rheumatology

Funding

  1. GlaxoSinithKline, Uxbridge, UK
  2. Human Genome Sciences Inc., Rockville, Maryland, USA
  3. GlaxoSmithKline (GSK)
  4. Human Genuine Sciences Inc. (HGS)
  5. GSK
  6. HGS

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.